Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Acta Psychiatrica Scandinavica

• Publication date

  2012-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1600-0447.2012.01853.xPMID 22432602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

  2013cited by this paper
• Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

  2012cited by this paper
• 1H-MRS at 4 Tesla in minimally treated early schizophrenia

  2010cited by this paper
• 10‐Year trends in the treatment and outcomes of patients with first‐episode schizophrenia

  2010cited by this paper
• Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

  2009cited by this paper
• Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop

  2009cited by this paper
• White Matter Alterations in Deficit Schizophrenia

  2008cited by this paper
• Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

  2007cited by this paper
• Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.

  2006cited by this paper
• Glutamate‐mediated glial injury: Mechanisms and clinical importance

  2006cited by this paper
• Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.

  2005cited by this paper
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

  2005cited by this paper
• Reliability and validity of Japanese version of the Mini‐International Neuropsychiatric Interview

  2005cited by this paper
• 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

  2004cited by this paper
• Pathways that make voices: white matter changes in auditory hallucinations.

  2004cited by this paper
• State-related changes in cerebral white matter may underlie psychosis exacerbation.

  2004cited by this paper
• Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.

  2003cited by this paper
• Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.

  2002cited by this paper
• The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

  2001cited by this paper
• Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia

  2001cited by this paper
• A glutamatergic deficiency model of schizophrenia

  1999cited by this paper
• In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics.

  1999cited by this paper
• Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.

  1999cited by this paper
• Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity

  1998cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.

  1998cited by this paper
• Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

  1997cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia.

  1994cited by this paper
• DSM-IV: Diagnostic and Statistical Manual of Mental Disorders

  1994cited by this paper
• Estimation of metabolite concentrations from localized in vivo proton NMR spectra

  1993cited by this paper
• Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis.

  1992cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper

• Glutamate concentrations and cognitive deficits in ultra-treatment-resistant schizophrenia: An exploratory and comparative 1H-MRS study.

  2024cites this paper
• Meta-analytic evidence of elevated choline, reduced N-acetylaspartate, and normal creatine in schizophrenia and their moderation by measurement quality, echo time, and medication status

  2023cites this paper
• Transforming Neurology and Psychiatry: Organ-specific PET Instrumentation and Clinical Applications.

  2023cites this paper
• Toward recovery in schizophrenia: Current concepts, findings, and future research directions

  2022cites this paper
• White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-Naïve First-Episode Psychosis Patients.

  2021cites this paper
• Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level

  2021cites this paper
• Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review

  2021cites this paper
• Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies

  2021cites this paper
• Omega-3 fatty acids in cause, prevention and management of violence in schizophrenia: Conceptualization and application

  2020cites this paper
• Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis

  2020cites this paper
• C- reactive protein in schizophrenia-spectrum disorders; relationship to cognitive functions and medications

  2019cites this paper
• Ultrastructural pathology of oligodendrocytes adjacent to microglia in prefrontal white matter in schizophrenia

  2018cites this paper
• Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

  2017cites this paper
• Evaluation of neuron-glia integrity by in vivo proton magnetic resonance spectroscopy: Implications for psychiatric disorders.

  2016cites this paper
• Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.

  2016cites this paper
• Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.

  2016cites this paper
• Title: Evaluation of Neuron-glia Integrity by in vivo Proton Magnetic Resonance Spectroscopy: Implications for Psychiatric Disorders

  2016cites this paper
• Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample

  2016cites this paper
• The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis

  2016cites this paper
• Tryptophan Metabolism and White Matter Integrity in Schizophrenia

  2016cites this paper
• [Neurobiology of schizophrenia: new findings from the structure to the molecules].

  2015cites this paper
• Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy

  2015cites this paper
• Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation

  2015cites this paper
• Effect of l-theanine on glutamatergic function in patients with schizophrenia

  2015cites this paper
• Chronic social isolation decreases glutamate and glutamine levels and induces oxidative stress in the rat hippocampus.

  2015cites this paper
• Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies

  2014influential citation
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

  2014cites this paper
• Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study.

  2014cites this paper
• A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation

  2014cites this paper
• Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

  2014influential citation
• Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

  2013cites this paper
• Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

  2013influential citation